OPRX

Over the past six months, OptimizeRx Corp. (OPRX) stock has experienced a significant decline of 59.2% over the past 12 months. In September 2026, the stock increased due to integration with OpenPath and expansion of its Natural Language Audience Builder, but saw a slight decrease after participating in a conference and a positive impact from a new advisor appointment. August 2026 saw a significant 24.72% increase following finance leadership appointments and Q2 2026 financial results, despite a 30% year-over-year revenue decline due to a managed service program wind-down and a large customer's absence, though gross margin improved. In July 2026, the stock had minor impacts related to a conference call announcement and a new CMO appointment. June 2026 saw increases from the launch of CopayCue™ and Natural Language Audience Builder, and participation in conferences. In May 2026, the company held its Q1 2026 earnings call, launched programmatic access to authenticated EHR advertising, and lowered its 2026 revenue outlook to between $95 million and $100 million due to softness in contracted revenues, a shift from managed services, and cautious spending from pharmaceutical clients.